A high value pharmacological platform dedicated to the real time study of Stimulatory immune checkpoint signaling pathways
The aim of the poster is to present several innovative BRET assays developed at Domain Therapeutics and dedicated to both inhibitory and stimulatory ICPs (PD-1, CTLA-4, 4-1BB).
These assays are able to study pharmacology of potential new drugs targeting these hot topic targets. The ICP Platform set up here shows a good accuracy and robustness and represents a strong and reliable technology for drug discovery dedicated to ICPs. Our spatio-temporal cell-based functional assays can support broad drug programs, including: High Throughput Functional Screening, Lead Optimization and Bioanalytical QC lot Release.